1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
The Ministry of Health, Labor and Welfare (MHLW) on January 29 ordered safety-related label revisions for a batch of medicines, including MSD’s PD-1 inhibitor Keytruda (pembrolizumab) and Daiichi Sankyo’s anticoagulant Lixiana (edoxaban). The label of Keytruda will newly add pancreatic…
To read the full story
Related Article
- PMDA Reviewing Safety Risks for Joyclu, Lixiana, Keytruda
January 7, 2025
- Blue Letter Issued to OA Drug Joyclu after Anaphylaxis Reports
June 2, 2021
REGULATORY
- Espha’s Januvia Generic on Approval Roster towards June Listing
February 18, 2025
- “Annual Reports” Allowed for CMC Changes with Minimal Impact: MHLW
February 17, 2025
- Japan to Approve EquMet Generics, More Copycats toward June Listing
February 17, 2025
- MHLW Lays Out Procedures for Transition to Trivalent Flu Shots
February 17, 2025
- J&J’s Lazcluze, Genmab’s Tivdak, and More Up for MHLW Panel Review on Feb. 27
February 14, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…